Expert honoured to work on Attenborough film
A university researcher has said it was a "huge honour" after he helped create the latest Sir David Attenborough documentary.
Dr Bryce Stewart, an associate professor at the university, worked with broadcasters on the film Ocean.
Dr Stewart's guidance was required when the crew showcased a carefully controlled study as part of the film to better understand the effects of dredging - a method of fishing which sees boats tow a heavy metal frame with a bag or net - on marine life.
He said: "It was a huge honour to work on the film Ocean with David Attenborough, and I had the privilege of helping film some of the scenes and advising on the script."
More news stories for Devon
Listen to the latest news for Devon
He said: "The film is stunningly beautiful while being highly confronting at times.
"However, it ends with a message of hope – that is, if you properly protect marine ecosystems and manage human activities sustainably, then the ocean can bounce back at an astonishing rate.
"Achieving that balance and recovery is the focus of my research at Plymouth."
As part of his involvement, Dr Stewart and colleagues at the Marine Biological Association worked closely with the production team to highlight environmental challenges and the importance of conservation work.
Ocean was originally released in cinemas worldwide, and will be available for streaming globally on National Geographic on 7 June and Disney+ from 8 June, in celebration of World Ocean Day.
Follow BBC Devon on X, Facebook and Instagram. Send your story ideas to spotlight@bbc.co.uk.
University announces potential loss of 200 jobs
Never too late to study, says 72-year-old student
University gets electric boat in net-zero push
University of Plymouth
Ocean - Silverback Films
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Doctors try 'poo pills' to flush out dangerous superbugs
UK doctors are attempting to clear dangerous superbug infections using "poo pills" containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data suggests superbugs can be flushed out of the dark murky depths of the bowel and replaced with a mix of healthy gut bacteria. It is a new approach to tackling infections that resist antibiotics, which are thought to kill a million people each year. The focus is on the bowels which are "the biggest reservoir of antibiotic resistance in humans" says Dr Blair Merrick, who has been testing the pills at Guys and St Thomas' hospitals. Drug-resistant superbugs can escape their intestinal home and cause trouble elsewhere in the body – such as urinary tract or bloodstream infections. "So there's a lot of interest in 'can you get rid of them from the gut?'," says Dr Merrick. The idea of poo-pills isn't as far-fetched as it might seem. Faecal transplants – also known as a trans-poo-tion - are already approved for treating severe diarrhoea caused by Clostridium difficile bacteria. But scientists noticed hints that faecal transplants for C. difficile also seemed to get rid of superbugs. Microbiome podcast: Manipulating Our Hidden Half New research has focused on patients who had an infection caused by drug-resistant bacteria in the past six months. They were given pills made from faeces which people had donated to a stool bank. Each stool sample is tested to ensure it does not contain any harmful bugs, undigested food is removed and then it is freeze dried into a powder. This is stored inside a pill that can pass through the stomach unscathed and reach the intestines where it dissolves to release its poopy powdery payload. The trial has taken place on 41 patients at Guy's and St Thomas' hospitals in London to lay the groundwork for a large-scale study. It showed patients were up for taking a poo pill and the donated bacteria were still being detected in the bowels at least a month later. Dr Merrick says there are "really promising signals" that poo pills could help tackle the rising scourge of superbugs and that donor bacteria could be going to microbial war with the superbugs as they compete over food and space on the lining of the gut and either rid the body of them completely or "reduce them down to a level that doesn't cause problems". The study also suggests the array of gut bacteria becomes more varied after the therapy. This is a sign of good health and "may well be promoting colonisation resistance" so it is harder for new infectious bugs to get in. "It's very exciting. There's a real shift from 20 years ago where all bacteria and viruses were assumed to do you harm; to now where we realise they are completely necessary to our overall health," says Dr Merrick. Earlier this week scientists showed the good bacteria our bodies meet – in the hours after we are born – seem to halve the risk of young children being admitted to hospital with lung infections. First bacteria we ever meet can keep us out of hospital More than half your body is not human Our body's own human cells are outnumbered by the bacteria, fungi and others that live inside us - known as the microbiome. This has led to research implicating the microbiome in everything from Crohn's disease to cancer to mental health. If poo pills are proven to work against superbugs in larger studies then the researchers think they could be used for both treatment and prevention in people at risk. Medical procedures that suppress the immune system - including cancer therapies and organ transplants - can make the body more vulnerable. "A lot of these individuals come to a lot of harm from drug resistant organisms," Dr Merrick. The UK's drugs regulator – the Medicines and Healthcare Products Agency – said there were more than 450 microbiome medicines currently in development. "Some of them will success, so I do think we will seem them coming through quite soon," said Dr Chrysi Sergaki, the head of microbiome research at the MHRA. "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."
Yahoo
3 hours ago
- Yahoo
Doctors try 'poo pills' to flush out dangerous superbugs
UK doctors are attempting to clear dangerous superbug infections using "poo pills" containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data suggests superbugs can be flushed out of the dark murky depths of the bowel and replaced with a mix of healthy gut bacteria. It is a new approach to tackling infections that resist antibiotics, which are thought to kill a million people each year. The focus is on the bowels which are "the biggest reservoir of antibiotic resistance in humans" says Dr Blair Merrick, who has been testing the pills at Guys and St Thomas' hospitals. Drug-resistant superbugs can escape their intestinal home and cause trouble elsewhere in the body – such as urinary tract or bloodstream infections. "So there's a lot of interest in 'can you get rid of them from the gut?'," says Dr Merrick. The idea of poo-pills isn't as far-fetched as it might seem. Faecal transplants – also known as a trans-poo-tion - are already approved for treating severe diarrhoea caused by Clostridium difficile bacteria. But scientists noticed hints that faecal transplants for C. difficile also seemed to get rid of superbugs. Microbiome podcast: Manipulating Our Hidden Half New research has focused on patients who had an infection caused by drug-resistant bacteria in the past six months. They were given pills made from faeces which people had donated to a stool bank. Each stool sample is tested to ensure it does not contain any harmful bugs, undigested food is removed and then it is freeze dried into a powder. This is stored inside a pill that can pass through the stomach unscathed and reach the intestines where it dissolves to release its poopy powdery payload. The trial has taken place on 41 patients at Guy's and St Thomas' hospitals in London to lay the groundwork for a large-scale study. It showed patients were up for taking a poo pill and the donated bacteria were still being detected in the bowels at least a month later. Dr Merrick says there are "really promising signals" that poo pills could help tackle the rising scourge of superbugs and that donor bacteria could be going to microbial war with the superbugs as they compete over food and space on the lining of the gut and either rid the body of them completely or "reduce them down to a level that doesn't cause problems". The study also suggests the array of gut bacteria becomes more varied after the therapy. This is a sign of good health and "may well be promoting colonisation resistance" so it is harder for new infectious bugs to get in. "It's very exciting. There's a real shift from 20 years ago where all bacteria and viruses were assumed to do you harm; to now where we realise they are completely necessary to our overall health," says Dr Merrick. Earlier this week scientists showed the good bacteria our bodies meet – in the hours after we are born – seem to halve the risk of young children being admitted to hospital with lung infections. First bacteria we ever meet can keep us out of hospital More than half your body is not human Our body's own human cells are outnumbered by the bacteria, fungi and others that live inside us - known as the microbiome. This has led to research implicating the microbiome in everything from Crohn's disease to cancer to mental health. If poo pills are proven to work against superbugs in larger studies then the researchers think they could be used for both treatment and prevention in people at risk. Medical procedures that suppress the immune system - including cancer therapies and organ transplants - can make the body more vulnerable. "A lot of these individuals come to a lot of harm from drug resistant organisms," Dr Merrick. The UK's drugs regulator – the Medicines and Healthcare Products Agency – said there were more than 450 microbiome medicines currently in development. "Some of them will success, so I do think we will seem them coming through quite soon," said Dr Chrysi Sergaki, the head of microbiome research at the MHRA. "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."
